IPP Bureau
Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets
By IPP Bureau - February 07, 2026
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets
Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke
By IPP Bureau - February 07, 2026
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026
By IPP Bureau - February 07, 2026
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease
By IPP Bureau - February 07, 2026
Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
Zydus receives USFDA ODD for Desidustat for the treatment of sickle cell disease
By IPP Bureau - February 07, 2026
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
Novo Nordisk threatens legal action over Hims & Hers ‘knockoff’ semaglutide pill
By IPP Bureau - February 07, 2026
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
Pfizer’s HYMPAVZI bags FDA priority review, targeting younger & hard-to-treat hemophilia patients
By IPP Bureau - February 07, 2026
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
£1bn London Cancer Hub expansion wins planning approval
By IPP Bureau - February 07, 2026
The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site
Aicuris’ Pritelivir delivers Phase 3 win in hard-to-treat herpes patients
By IPP Bureau - February 07, 2026
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
Apotex scores exclusive Canadian rights to testosterone therapy Nebido
By IPP Bureau - February 07, 2026
Under the agreement, Apotex’s branded division, Searchlight Pharma, will seek regulatory approval and handle marketing and distribution in Canada
Hologic’s Aptima HPV test bags FDA nod for primary cervical cancer screening
By IPP Bureau - February 07, 2026
Hologic has been at the forefront of cervical cancer screening for decades
Fitch upgrades Biocon Biologics outlook to positive, affirms ‘BB-’ rating
By IPP Bureau - February 07, 2026
Novo Medi Sciences launches ‘G.A.U.R.I.’ to drive immunization for underprivileged girls
By IPP Bureau - February 06, 2026
Novo Medi Sciences aims to reach millions nationwide and provide NEXIPOX PLUS vaccination against chickenpox to thousands of underprivileged girl children
Aarti Drugs reports strong Q3 FY26 performance, PAT surges 58% YoY
By IPP Bureau - February 06, 2026
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Revvity posts higher Q4 earnings, lifts 2026 outlook as diagnostics strength offsets margin pressure
By IPP Bureau - February 05, 2026
Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come
